keyword
MENU ▼
Read by QxMD icon Read
search

Pimavanserin

keyword
https://www.readbyqxmd.com/read/27857126/repeated-7-day-treatment-with-the-5-ht2c-agonist-lorcaserin-or-the-5-ht2a-antagonist-pimavanserin-alone-or-in-combination-fails-to-reduce-cocaine-vs-food-choice-in-male-rhesus-monkeys
#1
Matthew L Banks, S Stevens Negus
Cocaine use disorder is a global public health problem for which there are no Food and Drug Administration-approved pharmacotherapies. Emerging preclinical evidence has implicated both serotonin (5-HT) 2C and 2A receptors as potential mechanisms for mediating serotonergic attenuation of cocaine abuse-related neurochemical and behavioral effects. Therefore, the present study aim was to determine whether repeated 7-day treatment with the 5-HT2C agonist lorcaserin (0.1-1.0 mg/kg/day, intramuscular; 0.032-0.1 mg/kg/h, intravenous) or the 5-HT2A inverse agonist/antagonist pimavanserin (0...
November 18, 2016: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27830568/psychosis-in-parkinson-disease-a-review-of-etiology-phenomenology-and-management
#2
REVIEW
Niyatee Samudra, Neepa Patel, Kyle B Womack, Pravin Khemani, Shilpa Chitnis
Parkinson disease psychosis (PDP) is a common phenomenon in Parkinson disease (PD) patients treated with dopaminergic drugs, and is associated with high morbidity and mortality. It also correlates with depression and dementia, and can contribute to considerable caregiver stress and burnout. While symptoms can be relieved by decreasing doses or number of anti-PD medications, this may lead to an unacceptable worsening of motor function. When general medical or psychiatric conditions have been ruled out, and decreasing dopaminergic agents is not effective in treating psychosis, therapies include atypical antipsychotics, primarily clozapine and quetiapine...
December 2016: Drugs & Aging
https://www.readbyqxmd.com/read/27800022/evidence-for-the-use-of-pimavanserin-in-the-treatment-of-parkinson-s-disease-psychosis
#3
REVIEW
Harini Sarva, Claire Henchcliffe
Parkinson's disease (PD) is a progressive neurodegenerative disorder with both motor and nonmotor symptoms (NMS), leading to significant morbidity and caregiver burden. Psychosis is common but is under recognized by physicians. When present, it increases the patient's risk of hospitalization and nursing home placement and caregiver burden. Although the atypical antipsychotic agent, clozapine, has been considered the gold standard treatment, severe agranulocytosis in 0.38% of patients and more commonly milder leukopenia, resulting in frequent blood testing, limit its use...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27719624/treatment-possibilities-for-psychosis-in-parkinson-s-disease-with-an-emphasis-on-the-newly-approved-drug-pimavanserin
#4
Zsófia Majláth, Izabella Obál, László Vécsei
Parkinson's disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5 HT2a) triggered mechanisms...
October 6, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27609312/pimavanserin-for-the-treatment-of-parkinson-s-disease-psychosis
#5
Ines Chendo, Joaquim J Ferreira
INTRODUCTION: Parkinson´s disease (PD) is a synucleinopathy that affects millions of people worldwide and leads to progressive disability. Psychosis is highly prevalent in PD patients and is associated with poor prognosis. Until April 2016, there were no licensed drugs available in the United States of America (USA) for the treatment of PD psychosis (PDP). Pimavanserin is the first Food and Drug Administration approved medicine for the treatment of hallucinations and delusions associated with PDP...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27594111/reslizumab-ixekizumab-and-pimavanserin-tartrate
#6
Daniel A Hussar, Christine A Dimaculangan
No abstract text is available yet for this article.
September 2016: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/27565217/morphine-induced-straub-tail-reaction-in-mice-treated-with-serotonergic-compounds
#7
Irina V Belozertseva, Olga A Dravolina, Margarita A Tur, Marina G Semina, Edwin E Zvartau, Anton Yu Bespalov
Constitutively active 5-HT2 receptors have been suggested to contribute to motoneuronal excitability, muscle spasms and spasticity. Accordingly, 5-HT2C receptor inverse agonists have been demonstrated in pilot experiments to reduce spasticity in animal model of spasticity and patients with spinal cord injuries. Thus, 5-HT2C receptor inverse agonists may represent a novel class of anti-spasticity agents justifying a search for compounds with robust 5-HT2C receptor inverse agonist activity either among the existing medications or via a dedicated drug discovery program...
August 24, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27559192/sugammadex
#8
Dennis J Cada, Terri L Levien, Danial E Baker
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers...
July 2016: Hospital Pharmacy
https://www.readbyqxmd.com/read/27504063/pharmaceutical-approval-update
#9
Michele B Kaufman
Venetoclax (Venclexta) for chronic lymphocytic leukemia; riboflavin 5'-phosphate solutions (Photrexa Viscous and Photrexa) for progressive keratoconus; and pimavanserin (Nuplazid) for Parkinson's disease psychosis.
August 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/27504054/the-efficacy-and-safety-of-antipsychotic-medications-in-the-treatment-of-psychosis-in-patients-with-parkinson-s-disease
#10
REVIEW
Nevena Divac, Radan Stojanović, Katarina Savić Vujović, Branislava Medić, Aleksandar Damjanović, Milica Prostran
Psychotic symptoms are present in up to 50% of patients with Parkinson's disease. These symptoms have detrimental effects on patients' and caregivers' quality of life and may predict mortality. The pathogenesis of psychotic symptoms in Parkinson's disease is complex, but the use of dopaminergic medications is one of the risk factors. The treatment of psychotic symptoms in Parkinson's disease is complicated due to the ability of antipsychotic medications to worsen motor symptoms. The efficacy of clozapine in the treatment of psychosis in patients with Parkinson's disease has been confirmed in several clinical trials; however, the adverse effects and the necessity of blood count monitoring are the reasons why the use of this drug is challenging...
2016: Behavioural Neurology
https://www.readbyqxmd.com/read/27503570/mechanism-of-action-of-pimavanserin-in-parkinson-s-disease-psychosis-targeting-serotonin-5ht2a-and-5ht2c-receptors
#11
Stephen M Stahl
Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.
August 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27262680/pimavanserin-first-global-approval
#12
Anthony Markham
Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with Parkinson's disease may develop Parkinson's disease psychosis, which is associated with increased morbidity and mortality and has few treatment options. This article summarizes the milestones in the development of pimavanserin leading to this first approval for the treatment of hallucinations and delusions in patients with Parkinson's disease psychosis...
July 2016: Drugs
https://www.readbyqxmd.com/read/27261226/pimavanserin-approved-for-parkinson-s-related-hallucinations-delusions
#13
Kate Traynor
No abstract text is available yet for this article.
June 15, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27249096/pimavanserin-nuplazid-for-parkinson-s-disease-psychosis
#14
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2016: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/27245248/pimavanserin-an-inverse-agonist-antipsychotic-drug
#15
Robert H Howland
Approximately all clinically useful antipsychotic drugs have known activity as dopamine receptor antagonists, but many of these drugs also are inverse agonists at the serotonin-2A (5HT2A) receptor. Pimavanserin is an inverse agonist at the 5HT2A receptor, with a lower binding affinity at the serotonin-2C receptor and sigma 1 receptor, but no significant binding to dopamine or other receptors. Because of its unique pharmacology, pimavanserin was approved for the treatment of psychosis associated with Parkinson's disease, and it has a low risk for exacerbating motor symptoms compared to standard antipsychotic medications...
June 1, 2016: Journal of Psychosocial Nursing and Mental Health Services
https://www.readbyqxmd.com/read/27242287/effects-of-7-day-repeated-treatment-with-the-5-ht2a-inverse-agonist-antagonist-pimavanserin-on-methamphetamine-vs-food-choice-in-male-rhesus-monkeys
#16
Matthew L Banks
BACKGROUND: Preclinical drug vs. food choice is an emerging group of drug self-administration procedures that have shown predictive validity to clinical drug addiction. Emerging data suggest that serotonin (5-HT)2A receptors modulate mesolimbic dopamine function, such that 5-HT2A antagonists blunt the abuse-related neurochemical effects of monoamine transporter substrates, such as amphetamine or methamphetamine. Whether subchronic 5-HT2A antagonist treatment attenuates methamphetamine reinforcement in any preclinical drug self-administration procedure is unknown...
August 1, 2016: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/26908168/the-safety-tolerability-and-efficacy-of-pimavanserin-tartrate-in-the-treatment-of-psychosis-in-parkinson-s-disease
#17
Stefan Hermanowicz, Neal Hermanowicz
Parkinson's disease psychosis (PDP) is a common and often very disturbing component of Parkinson's disease (PD). PDP consists of hallucinations that are mainly visual and delusions that are often of a paranoid nature. These symptoms can be the most troubling and disruptive of all the manifestations of Parkinson's disease. Current treatment methods include the reduction of anti-Parkinson's medications, a strategy that may worsen the motor problems the medications are prescribed to alleviate, and the introduction of selected antipsychotic medications that carry with them the potential for troubling side effects and serious consequences...
June 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/26757194/serotonin-2a-receptor-inverse-agonist-as-a-treatment-for-parkinson-s-disease-psychosis-a-systematic-review-and-meta-analysis-of-serotonin-2a-receptor-negative-modulators
#18
REVIEW
Ichiro Yasue, Shinji Matsunaga, Taro Kishi, Kiyoshi Fujita, Nakao Iwata
BACKGROUND: There is uncertainty about the efficacy and tolerability of serotonin 2A (5-HT2A) receptor negative modulators for Parkinson's disease psychosis (PDP). OBJECTIVE: This is the first meta-analysis of randomized placebo-controlled trials (RCTs) testing negative modulators of the 5-HT2A receptor as a treatment for PDP. METHODS: The primary outcome was the Scale for Assessment of Positive Symptoms (SAPS)-hallucinations (H) and -delusions (D) scores (SAPS-H+D)...
2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/26744739/pimavanserin
#19
REVIEW
N S Hunter, K C Anderson, A Cox
Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP). Currently there are no FDA-approved medications in the United States for the treatment of PDP, although on September 2, 2014, the United States Food and Drug Administration granted breakthrough therapy status to pimavanserin, highlighting the unmet need for therapeutics in this class. Most antipsychotic medications worsen motor dysfunction due to dopamine antagonism, and all carry a black box warning for an increased risk of mortality in elderly patients with dementia-related psychosis...
November 2015: Drugs of Today
https://www.readbyqxmd.com/read/26576669/potential-serotonergic-agents-for-the-treatment-of-schizophrenia
#20
REVIEW
Ricardo P Garay, Michel Bourin, Evelyne de Paillette, Ludovic Samalin, Ahcène Hameg, Pierre-Michel Llorca
INTRODUCTION: For the last 30 years, drugs targeting serotonin receptors (5-HTR) have been intensively investigated in schizophrenia. New drugs targeting 5-HTRs are under development in patients with schizophrenia. AREAS COVERED: In this review, the authors describe the recent clinical trials for schizophrenia with selective serotonergic agents and provide an opinion on how the investigated drugs can help to fulfil current treatment needs. Clinical trials were found in US and EU clinical trial registries and in the medical literature...
2016: Expert Opinion on Investigational Drugs
keyword
keyword
109330
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"